8-K: Boston Scientific Exceeds Expectations with Strong Q3 2024 Results, Driven by Cardiovascular Growth

Boston Scientific reported robust third-quarter 2024 results, surpassing revenue guidance and achieving significant growth across its cardiovascular segment.

Summary

• Boston Scientific's net sales for the third quarter of 2024 reached $4.209 billion, representing a 19.4% increase on a reported basis compared to the same period last year.
• The company's operational and organic growth rates were also strong, at 19.5% and 18.2% respectively, exceeding the company's guidance range of 13 to 15 percent.
• GAAP net income attributable to Boston Scientific common stockholders was $469 million, or $0.32 per share, while adjusted EPS reached $0.63, surpassing the guidance range of $0.57 to $0.59 per share.
• The Cardiovascular segment led the growth with a 25% increase in reported net sales, while MedSurg grew by 10.3%.
• The United States saw the highest regional growth at 23.5% reported and operational growth.
• The company has updated its full-year 2024 guidance, estimating net sales growth of approximately 16.5% on a reported basis and 15% on an organic basis, with adjusted EPS between $2.45 and $2.47.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strong revenue growth, exceeding guidance, and strategic acquisitions. While GAAP EPS was down, the adjusted EPS beat expectations, and the overall tone is optimistic about future performance.

Positives

• The company exceeded its own revenue and adjusted EPS guidance for the third quarter of 2024.
• The Cardiovascular segment showed exceptional growth, indicating strong market demand for its products.
• The company received several regulatory approvals for new products, including the FARAWAVE NAV Ablation Catheter and the FARAPULSE PFA System in Japan.
• The acquisition of Silk Road Medical, Inc. expands the company's portfolio and market reach.
• The company has increased its full-year guidance for both net sales and adjusted EPS.

Negatives

• GAAP net income attributable to Boston Scientific common stockholders decreased to $469 million, or $0.32 per share, compared to $505 million, or $0.34 per share, in the prior year period.
• The company's GAAP EPS of $0.32 was below the guidance range of $0.36 to $0.38 per share.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including economic conditions, competitive pressures, and regulatory changes.
• Manufacturing, distribution, and supply chain disruptions could impact the company's ability to meet demand.
• Cybersecurity events and public health emergencies could also pose risks to the company's operations.
• Variations in outcomes of clinical trials and market studies could affect product approvals and market acceptance.
• The company's ability to successfully integrate acquisitions could impact its financial performance.

Future Outlook

The company anticipates continued growth, with full-year 2024 net sales growth estimated at approximately 16.5% on a reported basis and 15% on an organic basis, and adjusted EPS between $2.45 and $2.47. Fourth quarter net sales growth is estimated to be in a range of approximately 16.5 to 18.5 percent on a reported basis, and 14 to 16 percent on an organic basis, with adjusted EPS between $0.64 and $0.66.

Management Comments

• Mike Mahoney, chairman and chief executive officer, stated that the company's sustained high performance is a testament to the strength of their talented global team, differentiated portfolio and category leadership strategy.
• He also noted that the company continues to gain momentum driven by their product pipeline, clinical evidence and commercial execution that position them well for the long term.

Industry Context

The strong performance of Boston Scientific, particularly in the cardiovascular segment, reflects the ongoing demand for advanced medical technologies in this area. The company's focus on innovation and strategic acquisitions positions it well within the competitive medical device industry.

Comparison to Industry Standards

• Boston Scientific's 19.4% reported net sales growth in Q3 2024 is strong compared to other large medical device companies, such as Medtronic, which reported a 5.3% revenue increase in their most recent quarter.
• The 25% growth in the Cardiovascular segment is particularly notable, outpacing the growth rates of many competitors in this space, such as Abbott's cardiovascular division which reported 14.3% growth in their most recent quarter.
• The acquisition of Silk Road Medical is a strategic move to expand into the stroke prevention market, similar to how other companies like Stryker have grown through acquisitions in related fields.
• The company's adjusted EPS of $0.63 also compares favorably to the industry average, indicating strong profitability.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees may be motivated by the company's success and growth prospects.
• Customers will benefit from the company's innovative products and therapies.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower-risk borrower due to its strong financial performance.

Next Steps

• The company will continue to focus on product development and commercial execution.
• Boston Scientific will integrate the recently acquired Silk Road Medical, Inc.
• The company will continue to launch new products in various markets, including the ACURATE Prime Aortic Valve System in Europe.
• Management will discuss these results with analysts on a conference call.

Key Dates

Keywords

Boston Scientific, Medical Devices, Cardiovascular, Net Sales, EPS, FDA Approval, Acquisition, Organic Growth, Adjusted EPS, Financial Results